Rural Health
Resources by Topic: Pharmacy and prescription drugs
Projecting the Impact of the $2,000 Part D Out-Of-Pocket Cap for Medicare Part D Enrollees with High Prescription Drug Spending
Examines the impact of the Medicare Part D $2,000 cap on out-of-pocket prescription drugs. Provides projected savings according to low-income subsidy (LIS) status, state, and demographic characteristics, including urban, rural-micropolitan, rural-other, or unclassified geographic location.
Date: 01/2025
Sponsoring organization: HHS Office of the Assistant Secretary for Planning and Evaluation
view details
Examines the impact of the Medicare Part D $2,000 cap on out-of-pocket prescription drugs. Provides projected savings according to low-income subsidy (LIS) status, state, and demographic characteristics, including urban, rural-micropolitan, rural-other, or unclassified geographic location.
Date: 01/2025
Sponsoring organization: HHS Office of the Assistant Secretary for Planning and Evaluation
view details
Combating Antimicrobial Resistance During the COVID-19 Pandemic: Perceived Risks and Protective Practices
Explores the range of factors that impacted efforts to combat antimicrobial resistance (AMR) during the COVID-19 pandemic. Presents findings from an analysis of published scholarly sources and lessons learned from urban and rural healthcare professionals involved in antimicrobial stewardship. Includes rural references and considerations throughout.
Author(s): Casey Sullivan, Cody R. Fisher, Laurin Grabowsky, et al.
Date: 01/2025
Sponsoring organizations: Eastern Research Group, Inc., HHS Office of the Assistant Secretary for Planning and Evaluation
view details
Explores the range of factors that impacted efforts to combat antimicrobial resistance (AMR) during the COVID-19 pandemic. Presents findings from an analysis of published scholarly sources and lessons learned from urban and rural healthcare professionals involved in antimicrobial stewardship. Includes rural references and considerations throughout.
Author(s): Casey Sullivan, Cody R. Fisher, Laurin Grabowsky, et al.
Date: 01/2025
Sponsoring organizations: Eastern Research Group, Inc., HHS Office of the Assistant Secretary for Planning and Evaluation
view details
Mississippi State Department of Health 2025 Annual Report
Offers overview of public health indicators for residents of the state of Mississippi including mortality, teen birth rates, various health conditions, and vaccination. Discusses regulation and legislative changes, pharmaceutical programs, lab services, public health outreach, rural health and primary care, Health Professional Shortage Areas, and administrative updates.
Date: 2025
Sponsoring organization: Mississippi State Department of Health
view details
Offers overview of public health indicators for residents of the state of Mississippi including mortality, teen birth rates, various health conditions, and vaccination. Discusses regulation and legislative changes, pharmaceutical programs, lab services, public health outreach, rural health and primary care, Health Professional Shortage Areas, and administrative updates.
Date: 2025
Sponsoring organization: Mississippi State Department of Health
view details
Number of Licensed Pharmacies by Pennsylvania County as of May 2025
County-level Pennsylvania map showing numbers of licensed pharmacies, and shadings showing counties with fewer than 15, 15-99, and 100 or more pharmacies.
Date: 2025
Sponsoring organization: Center for Rural Pennsylvania
view details
County-level Pennsylvania map showing numbers of licensed pharmacies, and shadings showing counties with fewer than 15, 15-99, and 100 or more pharmacies.
Date: 2025
Sponsoring organization: Center for Rural Pennsylvania
view details
The Implementation Climate for Integrating Buprenorphine Prescribing into Rural Primary Care
Examines the climate in rural primary care settings to expand buprenorphine access for opioid use disorder (OUD). Analyzes interview feedback from primary care practitioners in rural Ohio regarding issues such as OUD treatment prioritization, compatibility of buprenorphine prescriptions in primary care settings, and buprenorphine access shortages.
Author(s): Cheyenne Fenstemaker, Elizabeth A. Abrams, Katherine King, et al.
Citation: Journal of General Internal Medicine, 40, 2879-2889
Date: 12/2024
view details
Examines the climate in rural primary care settings to expand buprenorphine access for opioid use disorder (OUD). Analyzes interview feedback from primary care practitioners in rural Ohio regarding issues such as OUD treatment prioritization, compatibility of buprenorphine prescriptions in primary care settings, and buprenorphine access shortages.
Author(s): Cheyenne Fenstemaker, Elizabeth A. Abrams, Katherine King, et al.
Citation: Journal of General Internal Medicine, 40, 2879-2889
Date: 12/2024
view details
Rural Independent Pharmacies Sustainability Strategy
Policy brief discussing unique challenges that threaten the stability of rural independent pharmacies. Offers policy recommendations to support rural independent pharmacies.
Author(s): Sagar Dugani, Vistrit Choudhary, Brian G. Williams
Date: 12/2024
Sponsoring organization: National Rural Health Association
view details
Policy brief discussing unique challenges that threaten the stability of rural independent pharmacies. Offers policy recommendations to support rural independent pharmacies.
Author(s): Sagar Dugani, Vistrit Choudhary, Brian G. Williams
Date: 12/2024
Sponsoring organization: National Rural Health Association
view details
Estimating the Effects of the Medicare $2 Drug List on Part D Enrollees
Discusses the Medicare $2 Drug List (M2DL) Model, which would allow Medicare Part D enrollees to purchase monthly drugs for $2 or less. Provides projected financial impact of the model, such as out of pocket (OOP) costs for individual drugs as well as OOP changes for enrollees, with breakdowns by demographic variables, including urban, rural-micropolitan, rural-other, or unclassified location.
Date: 12/2024
Sponsoring organization: HHS Office of the Assistant Secretary for Planning and Evaluation
view details
Discusses the Medicare $2 Drug List (M2DL) Model, which would allow Medicare Part D enrollees to purchase monthly drugs for $2 or less. Provides projected financial impact of the model, such as out of pocket (OOP) costs for individual drugs as well as OOP changes for enrollees, with breakdowns by demographic variables, including urban, rural-micropolitan, rural-other, or unclassified location.
Date: 12/2024
Sponsoring organization: HHS Office of the Assistant Secretary for Planning and Evaluation
view details
Understanding MAT Access in the Context of Unused MAT Capacity in the United States: When Increasing Rural MAT Capacity Is Not Enough
Examines the factors related to buprenorphine prescriptions to treat opioid use disorder (OUD) and the impacts of the federal DATA waiver to increase provider capacity. Utilizes multiple data sources to describe medication-assisted treatment (MAT) capacity, access, barriers, availability of MAT, and service area need in rural areas.
Author(s): Carolyn Carpenedo Mun, Rachel Zambrano, Eileen Tallman, et al.
Citation: Substance Abuse Treatment, Prevention, and Policy, 19, 47
Date: 12/2024
view details
Examines the factors related to buprenorphine prescriptions to treat opioid use disorder (OUD) and the impacts of the federal DATA waiver to increase provider capacity. Utilizes multiple data sources to describe medication-assisted treatment (MAT) capacity, access, barriers, availability of MAT, and service area need in rural areas.
Author(s): Carolyn Carpenedo Mun, Rachel Zambrano, Eileen Tallman, et al.
Citation: Substance Abuse Treatment, Prevention, and Policy, 19, 47
Date: 12/2024
view details
Pharmacy-Based Preventive Services for Opioid Use Disorder: A Survey of U.S. Pharmacists
Examines pharmacist perceptions related to addressing opioid use disorder (OUD) and substance use disorder (SUD) in their patients. Utilizes online survey data from 1,146 pharmacists to analyze pharmacist concerns about drug use; drug screenings, interventions, and referrals; and commitment and readiness to address OUD and SUD in their patients. Includes breakdowns of pharmacist demographics as well as rurality of pharmacy locations.
Author(s): Li-Tzy Wu, Jacquie King, Kathryn Hefner, et al.
Citation: Addiction Science & Clinical Practice, 19, 88
Date: 12/2024
view details
Examines pharmacist perceptions related to addressing opioid use disorder (OUD) and substance use disorder (SUD) in their patients. Utilizes online survey data from 1,146 pharmacists to analyze pharmacist concerns about drug use; drug screenings, interventions, and referrals; and commitment and readiness to address OUD and SUD in their patients. Includes breakdowns of pharmacist demographics as well as rurality of pharmacy locations.
Author(s): Li-Tzy Wu, Jacquie King, Kathryn Hefner, et al.
Citation: Addiction Science & Clinical Practice, 19, 88
Date: 12/2024
view details
Texas Cares Rx Annual Program Report
Reports on fiscal year 2024 costs, initiatives, feedback, and future considerations for Texas Cares Rx, a prescription drug cost savings program for uninsured Texans. Pages 9-11 summarize stakeholder feedback on rural health needs, including discussion of rural healthcare access gaps and pharmacy deserts.
Date: 12/2024
Sponsoring organization: Texas Health and Human Services
view details
Reports on fiscal year 2024 costs, initiatives, feedback, and future considerations for Texas Cares Rx, a prescription drug cost savings program for uninsured Texans. Pages 9-11 summarize stakeholder feedback on rural health needs, including discussion of rural healthcare access gaps and pharmacy deserts.
Date: 12/2024
Sponsoring organization: Texas Health and Human Services
view details